Fairmount Funds Management LLC Trevi Therapeutics, Inc. Transaction History

Fairmount Funds Management LLC

  • $615 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$2.11 - $2.47 $57,124 - $66,870
-27,073 Reduced 0.52%
5,163,287 $11.3 Million
Q2 2023

Aug 14, 2023
SELL
$1.8 - $3.44 $911,079 - $1.74 Million
-506,155 Reduced 8.89%
5,190,360 $12.4 Million
Q3 2022

Nov 09, 2022
BUY
$1.54 - $4.28 $6.27 Million - $17.4 Million
4,072,126 Added 250.69%
5,696,515 $8.77 Million
Q2 2022

Aug 15, 2022
BUY
$1.8 - $3.39 $2.92 Million - $5.51 Million
1,624,389 New
1,624,389 $4.57 Million

Others Institutions Holding TRVI

# of Institutions
96
Shares Held
57.1M
Call Options Held
136K
Put Options Held
5.4K
View Full List

About Trevi Therapeutics, Inc.

TRVI Quotes by TradingView
  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $247M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Fairmount Funds Management LLC Portfolio

Follow Fairmount Funds Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fairmount Funds Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fairmount Funds Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email